Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has received a consensus rating of “Hold” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.56.
SCMP has been the subject of several analyst reports. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 7th. B. Riley lifted their price target on shares of Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, December 6th. BidaskClub raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Finally, began coverage on shares of Sucampo Pharmaceuticals in a report on Wednesday, November 15th. They set a “buy” rating and a $14.00 price target on the stock.
Several institutional investors have recently made changes to their positions in SCMP. Trexquant Investment LP bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $122,000. Aperio Group LLC bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $137,000. Voya Investment Management LLC grew its holdings in Sucampo Pharmaceuticals by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 13,411 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 2,477 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $153,000. Finally, Hartford Investment Management Co. bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $165,000. 67.09% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/03/14/brokerages-set-sucampo-pharmaceuticals-inc-scmp-pt-at-20-56.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.